These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34779569)

  • 21. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series.
    Reynolds TR; Gilbert BW; Hall KM
    J Pharm Pract; 2021 Oct; 34(5):755-760. PubMed ID: 32089040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reprint of: Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
    Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
    J Am Pharm Assoc (2003); 2024; 64(4S):102156. PubMed ID: 39127933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.
    Bavalia R; Abdoellakhan R; Brinkman HJM; Brekelmans MPA; Hamulyák EN; Zuurveld M; Hutten BA; Westerweel PE; Olie RH; Ten Cate H; Kruip M; Middeldorp S; Meijer K; Coppens M
    Res Pract Thromb Haemost; 2020 May; 4(4):569-581. PubMed ID: 32548555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
    Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
    J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations.
    Lucas F; Lewis J; Grandoni J; Sylvester KW; Bernier TD; Ting C; Sek R; Ballard K; Connors JM; Battinelli EM
    Am J Clin Pathol; 2023 Dec; 160(6):571-584. PubMed ID: 37549067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The outcomes of three-factor prothrombin complex concentrate (3F-PCC) in warfarin anticoagulation reversal: a prospective, single-arm, open-label, multicentre study.
    Koh HP; Jagan N; George D; Mazlan-Kepli W; Mohamed S; Lim HT; Ross NT; Mazlan AM
    J Thromb Thrombolysis; 2021 Oct; 52(3):836-847. PubMed ID: 33748900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
    Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
    J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
    Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
    Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of Prothrombin Complex Concentrates Use in Apixaban and Rivaroxaban Associated Intracranial Hemorrhages.
    Ibarra F
    J Pharm Pract; 2022 Dec; 35(6):1012-1020. PubMed ID: 34036837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
    Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
    Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery.
    Schmidt LE; Hinton MS; Martin ND
    J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protocolized warfarin reversal with 4-factor prothrombin complex concentrate versus 3-factor prothrombin complex concentrate with recombinant factor VIIa.
    Barton CA; Hom M; Johnson NB; Case J; Ran R; Schreiber M
    Am J Surg; 2018 May; 215(5):775-779. PubMed ID: 29338845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombin generation in real life bleeding patients on oral anticoagulants reversed (or not) with (activated) prothrombin complex concentrate.
    Teissandier D; Moustafa F; Denaives A; Lebecque B; Blondonnet R; Pereira B; Monfoulet LE; Sinegre T; Schmidt J; Lebreton A
    Thromb Res; 2023 Mar; 223():184-193. PubMed ID: 36764085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
    Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
    Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.